Tests an antibiotic to prevent infections in people starting dialysis
Tests amoxicillin clavulanic acid against placebo in adults starting dialysis through a central catheter.
Plain-language title generated from the registry record
Registry title: Prophylactic Antibiotic Treatment in Hemodialysis
Key facts
- Where
- Aalborg, Aarhus, Copenhagen, Hillerød, Odense, and Roskilde, DenmarkSee the 7 sites
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkTaking people
- Aarhus University HospitalAarhus, DenmarkNot yet recruiting
- Herlev-Gentofte HospitalCopenhagen, DenmarkTaking people
- RigshospitaletCopenhagen, DenmarkNot yet recruiting
- North Zealand Hospital, HillerødHillerød, DenmarkNot yet recruiting
- Odense University HospitalOdense, DenmarkTaking people
- ZUH RoskildeRoskilde, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zealand University Hospital
- Trial code
- NCT05248620
- Record updated
- 10 September 2026
- Original description
The purpose of this study is to assess the efficacy of prophylactic antibiotic treatment on blood stream infections and severe culture negative infections, in patients on newly started hemodialysis(HD), with a central venous catheter as vascular access.Read full original descriptionShow less
Prophylactic Antibiotic Treatment in End Stage Kidney Disease and Central Venous Catheter as Hemodialysis Vascular Access
The purpose of this study is to assess the efficacy of prophylactic antibiotic treatment on blood stream infections and severe culture negative infections, in patients on newly started hemodialysis(HD), with a central venous catheter as vascular access.
Inclusion: End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV-fistula or AV-graft)); ≥18 years; Ability to understand the study background, risk and benefit of treatment and to give written informed consent.
Exclusion: Active infection treated with antibiotics; Pregnancy. In women of childbearing age, an approved birth control must be ensured at least 1 month before and during all the 6 months of antibiotic/placebo treatment; Patients may be rescreened later i.e. within a time period of one month from start of HD, if exclusion criteria are reversible; Unable to give informed consent; Known intolerance to beta-lactam antibiotics and clindamycin; Breastfeeding.